Detalles de la búsqueda
1.
Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials.
Ann Intern Med;
174(2): 221-228, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33090877
2.
A phase 3 randomized, open-label study evaluating the immunogenicity and safety of concomitant and staggered administration of a live, pentavalent rotavirus vaccine and an inactivated poliomyelitis vaccine in healthy infants in China.
Hum Vaccin Immunother;
20(1): 2324538, 2024 Dec 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-38509699
3.
Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial.
JAMA;
309(13): 1368-78, 2013 Apr 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-23549582
4.
Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials.
Vaccine;
40(46): 6599-6606, 2022 11 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36208978
5.
Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged ≥50 years: a randomized phase 3 trial (PNEU-FLU).
Hum Vaccin Immunother;
18(1): 1-14, 2022 12 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-34726574
6.
Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial.
EBioMedicine;
75: 103811, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-35042081
7.
Estimation of the correlates of protection of the rVSVΔG-ZEBOV-GP Zaire ebolavirus vaccine: a post-hoc analysis of data from phase 2/3 clinical trials.
Lancet Microbe;
2(2): e70-e78, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35544244
8.
Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults agedâ¯≥50â¯years: A randomized phase III trial (PNEU-PATH).
Vaccine;
39(43): 6422-6436, 2021 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34489128
9.
Sequential administration of Prevnar 13™ and PNEUMOVAX™ 23 in healthy participants 50 years of age and older.
Hum Vaccin Immunother;
17(8): 2678-2690, 2021 08 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34019468
10.
Using artificial intelligence tools in answering important clinical questions: The KEYNOTE-183 multiple myeloma experience.
Contemp Clin Trials;
99: 106179, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33086159
11.
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Hum Vaccin Immunother;
15(3): 540-548, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30427749
12.
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age.
Vaccine;
36(45): 6875-6882, 2018 10 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-29559167
13.
Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants.
Vaccine;
36(45): 6883-6891, 2018 10 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-30244873
14.
Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines.
Pediatr Infect Dis J;
25(4): 287-92, 2006 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-16567978
15.
The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
Pediatr Infect Dis J;
25(7): 615-22, 2006 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-16804432
16.
Safety and Immunogenicity of M-M-RII (Combination Measles-Mumps-Rubella Vaccine) in Clinical Trials of Healthy Children Conducted Between 1988 and 2009.
Pediatr Infect Dis J;
35(9): 1011-20, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27254037
17.
A double blind, randomized, active controlled study to assess the safety, tolerability and immunogenicity of measles, mumps rubella, and varicella vaccine (MMRV) manufactured using an alternative process.
Hum Vaccin Immunother;
12(8): 2188-2196, 2016 08 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27149048
18.
Safety, tolerability and immunogenicity of 15-valent pneumococcal conjugate vaccine in toddlers previously vaccinated with 7-valent pneumococcal conjugate vaccine.
Pediatr Infect Dis J;
34(2): 186-94, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25741971
19.
M-M-R(®)II manufactured using recombinant human albumin (rHA) and M-M-R(®)II manufactured using human serum albumin (HSA) exhibit similar safety and immunogenicity profiles when administered as a 2-dose regimen to healthy children.
Vaccine;
33(18): 2132-40, 2015 Apr 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-25796337
20.
Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults.
Vaccine;
33(24): 2793-9, 2015 Jun 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-25913828